在克罗恩病或成年人性结肠炎的2期和3期试验之间一致的疗效结果:元分析
Ziqi Wan1,2, Qingwei Jiang1, Runing Zhou1
1Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
概括
克罗恩病 (CD) 和性结肠炎 (UC) 试验中的疗效结果通常在第二阶段和第三阶段之间一致. 对于CD和UC的第二阶段数据是可靠的,用于设计第三阶段研究,除了UC反应率.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
- 生物统计学 生物统计学
背景情况:
- 克罗恩病 (CD) 和性结肠炎 (UC) 的生物药物和小分子需要第三阶段随机对照试验 (RCT) 才能获得批准.
- 第三阶段RCT有时会产生与早期第二阶段试验中观察到的不同疗效结果.
研究的目的:
- 系统地审查和比较2期和3期随机对照试验 (RCT) 之间的生物制剂和CD和UC中小分子的疗效结果.
- 评估第二阶段疗效数据的可靠性,以告知第三阶段试验设计.
主要方法:
- 对评价CD和UC的2期和3期配对治疗方案的RCT进行系统审查.
- 搜索了Medline,EMBASE和Cochrane数据库,截至2024年2月13日.
- 利用修订后的Cochrane工具进行偏差风险评估和通用线性混合效应模型 (GLMM) 来比较第二阶段和第三阶段的疗效结果.
主要成果:
- 对于CD,第二阶段试验在CDAI措施中显示了数值上更高的疗效 (9-13%) 但缺乏统计学意义.
- 对于UC,临床缓解和内镜改善在2期和3期之间是相似的 (ORs ~1.00).
- 在第二阶段试验中,UC临床响应率被低估了 (OR 0.81,p=0.03),与梅奥得分纳入标准的显著相互作用.
结论:
- 对CD和UC的有效性结果在第二阶段和第三阶段试验之间基本一致.
- 第2阶段疗效数据通常可靠用于第3阶段试验设计,除了UC反应率.
- 这些发现支持在规划IBD治疗药物的后续临床试验时继续使用2期数据.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
136
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
136
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


